ENLIVEX LTD (ENLV) Stock Price & Overview
NASDAQ:ENLV • IL0011319527
Current stock price
The current stock price of ENLV is 0.8382 USD. Today ENLV is down by -12.82%. In the past month the price decreased by -19.4%. In the past year, price decreased by -2.53%.
ENLV Key Statistics
- Market Cap
- 198.972M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -8.17
- Dividend Yield
- N/A
ENLV Stock Performance
ENLV Stock Chart
ENLV Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ENLV. When comparing the yearly performance of all stocks, ENLV is a bad performer in the overall market: 77.74% of all stocks are doing better.
ENLV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ENLV. ENLV has a great financial health rating, but its profitability evaluates not so good.
ENLV Earnings
ENLV Forecast & Estimates
8 analysts have analysed ENLV and the average price target is 13.26 USD. This implies a price increase of 1481.96% is expected in the next year compared to the current price of 0.8382.
ENLV Groups
Sector & Classification
ENLV Financial Highlights
Over the last trailing twelve months ENLV reported a non-GAAP Earnings per Share(EPS) of -8.17. The EPS decreased by -1019.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.66% | ||
| ROE | -72.66% | ||
| Debt/Equity | 0 |
ENLV Ownership
ENLV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 365.196B | ||
| AMGN | AMGEN INC | 15.32 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 10.94 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.34 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ENLV
Company Profile
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Company Info
IPO: 2014-07-30
ENLIVEX LTD
14 Einstein St.
Ness Ziona 7403618 IL
CEO: Oren Hershkovitz
Employees: 36
Phone: 97286623301
ENLIVEX LTD / ENLV FAQ
What does ENLV do?
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
What is the current price of ENLV stock?
The current stock price of ENLV is 0.8382 USD. The price decreased by -12.82% in the last trading session.
What is the dividend status of ENLIVEX LTD?
ENLV does not pay a dividend.
How is the ChartMill rating for ENLIVEX LTD?
ENLV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ENLIVEX LTD (ENLV) based on its PE ratio?
ENLIVEX LTD (ENLV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.17).
Can you provide the upcoming earnings date for ENLIVEX LTD?
ENLIVEX LTD (ENLV) will report earnings on 2026-05-25.
Who owns ENLIVEX LTD?
You can find the ownership structure of ENLIVEX LTD (ENLV) on the Ownership tab.